Kura Oncology is trading at $7.15, up 5.15%, apparently reflecting a broader rebound rather than a clear company-specific catalyst.
- Reuters reported the Nasdaq was rising as chip stocks recovered from heavy losses amid renewed buying interest.
- The October jobs report showed 165,000 jobs added, above the 65,000 expected, while also raising interest-rate concerns.
- Kura announced routine stock-option inducement grants on November 6, disclosing grants approved November 2; the announcement does not establish a reason for the share move.